~" A course of small doses of heparin given subcutaneously before and after elective operations has been reported to reduce the incidence of deep venous thrombosis and pulmonary embolism in general surgical patients. To test the safety of mini-dose heparin for neurosurgical patients, mini-dose heparin was used for 150 adult patients undergoing elective neurosurgical procedures. No operative complications were thought to be related to heparin administration. Postoperatively, there were four wound seromas, two hematomas, and one non-fatal pulmonary embolus. Seven patients died postoperatively, of whom five had no evidence of pulmonary embolus. Although no conclusions were drawn as to the effectiveness of mini-dose heparin in preventing deep venous thrombosis or pulmonary emboli, it was believed that the method could be used safely and without fear of increased intracranial or intraspinal bleeding for neurosurgical patients.
D
EEP venous thrombosis and pulmonary embolism continue to be a source of morbidity and mortality to postoperative and severely injured patients. It has been estimated that pulmonary emboli cause 50-to 100-thousand deaths per year in this country, and account for 10% of all postoperative deaths? 5 In 1934, Homans 4 was one of the first to describe deep venous thrombosis, from which fully 95% of pulmonary emboli arise. Several authors 8,~~ have reported that 30% to 45% of patients undergoing general surgery develop deep venous thrombosis. Coon and Coller ~ reported that 20% of patients with clinical deep venous thrombosis develop a pulmonary embolus, and among these there is an 18% mortality.
If clinical or physical signs only are relied upon, deep venous thrombosis will be missed in 50% of cases? With a25I fibrinogen scanning, Kakkar, et al., 9 have determined that deep venous thrombosis occurs in 30% of general-surgery patients, in 54% of orthopedic-surgery patients, and in 50% of urological-surgery patients. Also using radionuclide venous scanning, Joffe 5 recently reported a 43% incidence of postoperative deep venous thrombosis in neurosurgical patients. Of these patients, 90% were asymptomatic.
In 1950, DeTakats ~ said that it takes much less heparin to prevent clotting than it does to treat it and introduced mini-dose heparin therapy. Sharnoff, et al.," advocated prophylactic heparinization of surgical patients in 1962, and Kakkar and his associates 9,~~ have done much of the recent work on mini-dose heparin. Nicolaides, et al.,~2 reported a study of 251 postoperative patients using radionuclide scanning. In his control group (no heparin therapy), 24% had deep venous thrombosis and 7.4% had pulmonary emboli. Of the patients in the test group treated with mini-dose heparin, 0.8% had deep venous thrombosis and none had embolus. Other authors s,e,le have reported an apparent reduction in the incidence of deep venous thrombosis and pulmonary emboli when mini-dose heparin therapy was used for general surgical and orthopedic procedures (Table 1) . However, we know of no studies of mini-dose heparin therapy for neurosurgical patients. In fact, Youmans 17 writes that he does not use prophylactic anticoagulants because of the danger of relying on soft-tissue tamponade to control bleeding intracranially and intraspinally. We instituted the following study to evaluate the safety of giving pre-and postoperative heparin to neurosurgical patients.
Clinical Material and Method
We selected for the study 150 adult patients undergoing elective neurosurgical procedures at the Veterans Administration Hospital, New Orleans, and the Tulane Service of Charity Hospital, New Orleans. All patients were questioned carefully about bleeding disorders and previous history of deep venous thrombosis or pulmonary embolus. They were also evaluated by determination of platelet count, prothrombin time, and partial thromboplastin time. If these determinations were within normal limits, 5000 units of aqueous heparin sodium were given subcutaneously with the preoperative medicines and every 12 hours postoperatively as long as the patients were confined to bed. Thus, the duration of postoperative heparin therapy varied, but all patients received heparin for at least 3 days postoperatively. The procedures performed on the 150 patients represent a broad spectrum of neurosurgical procedures ( Table 2 ).
Summary of Cases
No complications thought to be related to heparin administration were observed at surgery (Table 3 ). There was no excessive bleeding or difficulty with hemostasis. Postoperatively, four wound seromas required aspiration. There were two wound hematomas: one was an anterior cervical fusion wound that required aspiration; the other was a postoperative clot in the tumor bed of a metastatic intracranial lesion removed at reoperation with no further bleeding. One patient developed a non-fatal pulmonary embolus, clinically detectable and confirmed by lung scanning, on the 12th day after removal of a brain tumor. This patient had received heparin for the first 6 days following surgery. He was thereupon fully anticoagulated, and recovered from his pulmonary embolus.
Seven patients died, and postmortem examinations were done in six. Four showed no evidence of deep venous thrombosis or pulmonary emboli; one showed evidence of many small pulmonary emboli, but death was attributed to a myocardial infarction. The remaining autopsy showed the cause of death to be a massive pulmonary embolus 15 days after removal of a meningioma. The heparin therapy had been stopped on the fifth day after surgery. In the one death with no autopsy performed, there was no clinical evidence of deep venous thrombosis or pulmonary embolus and the cause of death was pneumonia.
Discussion
How can small quantities of heparin, in amounts that will not diminish the whole blood clotting time, possibly provide anticoagulation protection? Several authors have addressed themselves to this frequently asked and intriguing question. There is a potent, naturally occurring inhibitor to activated factor X in human plasma. This inhibitor, antithrombin III, is enhanced by heparin. Activated factor X occupies a key position in the intrinsic and extrinsic coagulation mechanisms. If heparin is administered before tissue trauma activates factor X, then low doses of heparin are adequate to prevent thrombus. If heparin is not given until after tissue trauma, then larger doses are needed to neutralize it.
Negus, et al.," believe that mini-dose heparin has an effect on platelet adhesiveness and lipoprotein activity before and after surgery. Adherence of platelets to each other and to the vascular endothelium is thought to be an important factor in the initiation of venous thrombosis. Platelet adhesiveness appears to increase on the second postoperative day. Sharnoff 18 reports two transient hypercoagulable periods. One is the operative period and the other is the period of patient reactivation after immobilization. He feels that these periods of hypercoagulability are related to the release of megakaryocytes trapped in the lung.
A certain group of surgical patients are at high risk for the development of postoperative deep venous thrombosis and pulmonary embolus. This includes patients with 1) a previous history of hypercoagulable state; 2) prolonged immobilization; 3) obesity; 4) advanced age; 5) cardiac disease; 6) malignancy; and 7) varicose veins. Kakkar, et al., ~~ would add to this group any patients having a previous history of deep venous thrombosis, 68% of whom will develop deep venous thrombosis again in the postoperative period.
The purpose of this study was not to test the effectiveness of mini-dose heparin in preventing deep venous thrombosis or pulmonary emboli, and we do not believe any valid conclusions in this regard can be drawn. We do believe that we have shown that minidose heparin therapy can be used safely and without fear of increased intracranial or intraspinal bleeding. Mini-dose heparin is not administered to create anticoagulation in the classic sense, but to prevent hypercoagulability.
Others have shown that there is a high incidence of clinically non-detectable deep venous thrombosis in the postoperative patient and that this incidence can be lowered when the patient is treated with perioperative mini-dose heparin. In Kakkar's preliminary results from a multicenter trial involving 2400 patients, as reported by Joffe, e fatal pulmonary emboli occurred in seven patients in the control group and in only one in the treated group. We feel that the administration of perioperative mini-dose heparin to the neurosurgical patient, particularly those in the high-risk group, may well decrease the incidence of deep venous thrombosis and pulmonary embolus. It is simple, safe, and inexpensive, and does not place the patient at any increased risk because of the heparin administration.
